Muminov M, Tsiferova N, Pshenichnov E, Ermatova K, Charishnikova O, Abdullaev A
Vaccines (Basel). 2025; 12(12.
PMID: 39772081
PMC: 11680381.
DOI: 10.3390/vaccines12121420.
Hardtke-Wolenski M, Landwehr-Kenzel S
Mol Cell Pediatr. 2024; 11(1):3.
PMID: 38507159
PMC: 10954601.
DOI: 10.1186/s40348-024-00176-8.
Coomans de Brachene A, Alvelos M, Szymczak F, Zimath P, Castela A, Marmontel de Souza B
Diabetologia. 2024; 67(5):908-927.
PMID: 38409439
DOI: 10.1007/s00125-024-06106-7.
Yang J, Li S
Front Pharmacol. 2023; 14:1118804.
PMID: 37361229
PMC: 10285311.
DOI: 10.3389/fphar.2023.1118804.
Harkins A, Kopec A, Keeler A
Crit Rev Immunol. 2023; 42(2):1-27.
PMID: 37017285
PMC: 11465901.
DOI: 10.1615/CritRevImmunol.2022045080.
The long and winding road: From mouse linkage studies to a novel human therapeutic pathway in type 1 diabetes.
Rojas M, Heuer L, Zhang W, Chen Y, Ridgway W
Front Immunol. 2022; 13:918837.
PMID: 35935980
PMC: 9353112.
DOI: 10.3389/fimmu.2022.918837.
Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer.
Li M, Zhang X, Bai X, Liang T
Front Oncol. 2022; 12:862154.
PMID: 35494080
PMC: 9048045.
DOI: 10.3389/fonc.2022.862154.
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome as a Hyper-Regulated Immune System Driven by an Interplay Between Regulatory T Cells and Chronic Human Herpesvirus Infections.
Sepulveda N, Carneiro J, Lacerda E, Nacul L
Front Immunol. 2019; 10:2684.
PMID: 31824487
PMC: 6883905.
DOI: 10.3389/fimmu.2019.02684.
Targeting Regulatory T Cells by Addressing Tumor Necrosis Factor and Its Receptors in Allogeneic Hematopoietic Cell Transplantation and Cancer.
Wajant H, Beilhack A
Front Immunol. 2019; 10:2040.
PMID: 31555271
PMC: 6724557.
DOI: 10.3389/fimmu.2019.02040.
High Thymic Output of Effector CD4 Cells May Lead to a Treg : T Effector Imbalance in the Periphery in NOD Mice.
Zhao Y, Alard P, Kosiewicz M
J Immunol Res. 2019; 2019:8785263.
PMID: 31281853
PMC: 6594269.
DOI: 10.1155/2019/8785263.
Genetic and functional data identifying Cd101 as a type 1 diabetes (T1D) susceptibility gene in nonobese diabetic (NOD) mice.
Mattner J, Mohammed J, Fusakio M, Giessler C, Hackstein C, Opoka R
PLoS Genet. 2019; 15(6):e1008178.
PMID: 31199784
PMC: 6568395.
DOI: 10.1371/journal.pgen.1008178.
Type 1 diabetes pathogenesis and the role of inhibitory receptors in islet tolerance.
Martinov T, Fife B
Ann N Y Acad Sci. 2019; 1461(1):73-103.
PMID: 31025378
PMC: 6994200.
DOI: 10.1111/nyas.14106.
Nrf2 represses the onset of type 1 diabetes in non-obese diabetic mice.
Yagishita Y, Uruno A, Chartoumpekis D, Kensler T, Yamamoto M
J Endocrinol. 2019; .
PMID: 30625116
PMC: 6602871.
DOI: 10.1530/JOE-18-0355.
Treatment of T1D via optimized expansion of antigen-specific Tregs induced by IL-2/anti-IL-2 monoclonal antibody complexes and peptide/MHC tetramers.
Izquierdo C, Ortiz A, Presa M, Malo S, Montoya A, Garabatos N
Sci Rep. 2018; 8(1):8106.
PMID: 29802270
PMC: 5970271.
DOI: 10.1038/s41598-018-26161-6.
Role of TNF-TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications.
Yang S, Wang J, Brand D, Zheng S
Front Immunol. 2018; 9:784.
PMID: 29725328
PMC: 5916970.
DOI: 10.3389/fimmu.2018.00784.
Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology.
Salomon B, Leclerc M, Tosello J, Ronin E, Piaggio E, Cohen J
Front Immunol. 2018; 9:444.
PMID: 29593717
PMC: 5857565.
DOI: 10.3389/fimmu.2018.00444.
The islet-resident macrophage is in an inflammatory state and senses microbial products in blood.
Ferris S, Zakharov P, Wan X, Calderon B, Artyomov M, Unanue E
J Exp Med. 2017; 214(8):2369-2385.
PMID: 28630088
PMC: 5551574.
DOI: 10.1084/jem.20170074.
Are Regulatory T Cells Defective in Type 1 Diabetes and Can We Fix Them?.
Visperas A, Vignali D
J Immunol. 2016; 197(10):3762-3770.
PMID: 27815439
PMC: 5119643.
DOI: 10.4049/jimmunol.1601118.
Neutralization Versus Reinforcement of Proinflammatory Cytokines to Arrest Autoimmunity in Type 1 Diabetes.
Kaminitz A, Ash S, Askenasy N
Clin Rev Allergy Immunol. 2016; 52(3):460-472.
PMID: 27677500
DOI: 10.1007/s12016-016-8587-y.
Mechanisms of autoimmunity in the non-obese diabetic mouse: effector/regulatory cell equilibrium during peak inflammation.
Askenasy N
Immunology. 2016; 147(4):377-88.
PMID: 26749404
PMC: 4799883.
DOI: 10.1111/imm.12581.